Canaccord Genuity Maintains Buy on TransMedics Gr, Lowers Price Target to $86
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst William Plovanic maintains a Buy rating on TransMedics Gr (NASDAQ:TMDX) and lowers the price target from $91 to $86.
May 18, 2023 | 11:56 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity maintains Buy rating on TransMedics Gr (TMDX) and lowers the price target from $91 to $86.
The news of Canaccord Genuity maintaining a Buy rating on TransMedics Gr (TMDX) is positive for the stock. However, the lowering of the price target from $91 to $86 may create some uncertainty among investors, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100